原发性胆汁性胆管炎（PBC）作为一种慢性自身免疫性肝病，已经逐渐引起了社会的广泛关注。根据最新数据显示，中国在2023年的PBC发病人数达到了28.7万人。该疾病以肝内胆汁淤积为主要特征，严重时可能导致肝硬化等严重后果。如今，PBC的认知逐渐加深，患者的发现率也在逐年提高，随之而来的，更是对治疗药物的需求不断增加。

展望未来，PBC药物行业呈现回暖迹象。随着技术的日益进步与临床实践的积累，新的高效治疗方案将不断涌现。根据《2025-2031年中国PBC药物行业市场调查研究报告》，我们可以清晰地看到，投资于这一领域的机会和挑战并存。如何把握这一趋势，加强行业的自律与创新，将是行业相关企业必须考虑的首要问题。

熊去氧胆酸（ursodeoxycholic acids, UDCA）是PBC的一线治疗药物，推荐剂量为13～15 mg·kg-1·d-1，分次或一次服用。研究表明UDCA可以改善PBC患者生化指标 ...

治疗对UDCA单药应答不足的原发性胆汁性胆管炎（PBC）患者；或者作为单药，治疗对UDCA治疗不耐受的PBC患者。 Seladelpar是目前首个且唯一在生化反应 ...

The US agency has cleared seladelpar under the Livdelzi brand name as a second-line therapy for PBC in adults, either in combination with ursodeoxycholic acid (UDCA) or as monotherapy for those ...

UDCA has, therefore, been evaluated for the treatment of patients with PSC. Trials of UDCA at low doses (10–15 mg/kg per day and 17–20 mg/kg per day) have yielded inconclusive results in ...

Many different drugs have been used in an attempt to slow the progression of PBC. The results have been variable. UDCA currently is the only drug approved by the U.S. Food and Drug Administration ...

Iqirvo (elafibranor) is also the first new therapy for PBC in more than a decade, getting a green light as a second-line therapy in combination with ursodeoxycholic acid (UDCA) in adult patients ...

Unlike PSC, PBC does not increase the risk of cancer, but it can still cause serious liver disease if untreated. The main treatment is ursodeoxycholic acid (UDCA), which helps slow the disease and ...

The analysis revealed that 81% of individuals treated with Livdelzi achieved a composite biochemical response.

Degree of benefit with UDCA is uncertain. Aim: To Look at Mode of diagnosis for CFALD and Effectiveness & safety of UDCA in our unit. Methods: Retrospective review on all patients currently ...

Primary biliary cholangitis (PBC) can deliver a significant blow to patients' quality of life, especially if they are not ...